Which has preferable valuation and earnings, CLGN or ZJYL?

Jin Medical International has higher revenue and earnings than CollPlant Biotechnologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CollPlant Biotechnologies $2.37M 2.18 -$11.49M -$1.45 N/A Jin Medical International $20.69M 0.72 $1.19M N/A N/A

Does the media favor CLGN or ICCM?

In the previous week, IceCure Medical had 12 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 15 mentions for IceCure Medical and 3 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.96 beat IceCure Medical's score of 0.50 indicating that CollPlant Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CollPlant Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IceCure Medical 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor HIND or CLGN?

In the previous week, Vyome and Vyome both had 3 articles in the media. CollPlant Biotechnologies' average media sentiment score of 0.96 beat Vyome's score of 0.93 indicating that CollPlant Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vyome 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CollPlant Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend OSRH or CLGN?

CollPlant Biotechnologies has a consensus price target of $11.50, indicating a potential upside of 3,112.29%. Given CollPlant Biotechnologies' stronger consensus rating and higher probable upside, analysts clearly believe CollPlant Biotechnologies is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CollPlant Biotechnologies 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to OSRH or CLGN?

In the previous week, CollPlant Biotechnologies had 1 more articles in the media than OSR. MarketBeat recorded 3 mentions for CollPlant Biotechnologies and 2 mentions for OSR. CollPlant Biotechnologies' average media sentiment score of 0.96 beat OSR's score of 0.62 indicating that CollPlant Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OSR 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CollPlant Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CollPlant Biotechnologies (CLGN) Competitors

$0.36 +0.01 (+2.61%)

As of 11:07 AM Eastern

Compare

CLGN vs. ZJYL, TMDIF, ICCM, HIND, and OSRH

Should you buy CollPlant Biotechnologies stock or one of its competitors? MarketBeat compares CollPlant Biotechnologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CollPlant Biotechnologies include Jin Medical International (ZJYL), Titan Medical (TMDIF), IceCure Medical (ICCM), Vyome (HIND), and OSR (OSRH). These companies are all part of the "medical equipment" industry.

How does CollPlant Biotechnologies compare to Jin Medical International?

CollPlant Biotechnologies (NASDAQ:CLGN) and Jin Medical International (NASDAQ:ZJYL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

CollPlant Biotechnologies presently has a consensus price target of $11.50, suggesting a potential upside of 3,112.29%. Given CollPlant Biotechnologies' stronger consensus rating and higher possible upside, equities analysts clearly believe CollPlant Biotechnologies is more favorable than Jin Medical International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Jin Medical International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Jin Medical International had 1 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 4 mentions for Jin Medical International and 3 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.96 beat Jin Medical International's score of 0.22 indicating that CollPlant Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CollPlant Biotechnologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jin Medical International	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

21.7% of CollPlant Biotechnologies shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CollPlant Biotechnologies has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, Jin Medical International has a beta of 7.23, meaning that its stock price is 623% more volatile than the broader market.

Jin Medical International has higher revenue and earnings than CollPlant Biotechnologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	2.18	-$11.49M	-$1.45	N/A
Jin Medical International	$20.69M	0.72	$1.19M	N/A	N/A

Jin Medical International has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -683.68%. Jin Medical International's return on equity of 0.00% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%
Jin Medical International	N/A	N/A	N/A

Summary

CollPlant Biotechnologies and Jin Medical International tied by winning 7 of the 14 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to Titan Medical?

CollPlant Biotechnologies (NASDAQ:CLGN) and Titan Medical (NASDAQ:TMDIF) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

CollPlant Biotechnologies has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market. Comparatively, Titan Medical has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

Titan Medical has higher revenue and earnings than CollPlant Biotechnologies. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	2.18	-$11.49M	-$1.45	N/A
Titan Medical	$17.63M	1.07	$6.95M	$0.05	3.30

In the previous week, CollPlant Biotechnologies had 3 more articles in the media than Titan Medical. MarketBeat recorded 3 mentions for CollPlant Biotechnologies and 0 mentions for Titan Medical. CollPlant Biotechnologies' average media sentiment score of 0.96 beat Titan Medical's score of 0.00 indicating that CollPlant Biotechnologies is being referred to more favorably in the media.

Company	Overall Sentiment
CollPlant Biotechnologies	Positive
Titan Medical	Neutral

21.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 0.0% of Titan Medical shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by insiders. Comparatively, 0.0% of Titan Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Titan Medical has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -683.68%. Titan Medical's return on equity of -82.31% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%
Titan Medical	N/A	-82.31%	-51.47%

CollPlant Biotechnologies presently has a consensus price target of $11.50, indicating a potential upside of 3,112.29%. Given CollPlant Biotechnologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe CollPlant Biotechnologies is more favorable than Titan Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

CollPlant Biotechnologies beats Titan Medical on 9 of the 16 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to IceCure Medical?

CollPlant Biotechnologies (NASDAQ:CLGN) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

In the previous week, IceCure Medical had 12 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 15 mentions for IceCure Medical and 3 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.96 beat IceCure Medical's score of 0.50 indicating that CollPlant Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CollPlant Biotechnologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IceCure Medical	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CollPlant Biotechnologies has higher earnings, but lower revenue than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	2.18	-$11.49M	-$1.45	N/A
IceCure Medical	$3.38M	5.40	-$15.06M	-$7.21	N/A

21.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by company insiders. Comparatively, 2.4% of IceCure Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CollPlant Biotechnologies currently has a consensus target price of $11.50, indicating a potential upside of 3,112.29%. IceCure Medical has a consensus target price of $62.70, indicating a potential upside of 1,077.46%. Given CollPlant Biotechnologies' higher probable upside, research analysts plainly believe CollPlant Biotechnologies is more favorable than IceCure Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IceCure Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

IceCure Medical has a net margin of -441.60% compared to CollPlant Biotechnologies' net margin of -683.68%. IceCure Medical's return on equity of -211.73% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%
IceCure Medical	-441.60%	-211.73%	-119.13%

CollPlant Biotechnologies has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market. Comparatively, IceCure Medical has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

Summary

CollPlant Biotechnologies and IceCure Medical tied by winning 8 of the 16 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to Vyome?

Vyome (NASDAQ:HIND) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

Vyome has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, CollPlant Biotechnologies has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market.

22.1% of Vyome shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 33.0% of Vyome shares are owned by company insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Vyome has a net margin of -270.58% compared to CollPlant Biotechnologies' net margin of -683.68%. Vyome's return on equity of -203.92% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vyome	-270.58%	-203.92%	-134.16%
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%

Vyome has higher earnings, but lower revenue than CollPlant Biotechnologies. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$320K	48.57	-$10.26M	-$12.27	N/A
CollPlant Biotechnologies	$2.37M	2.18	-$11.49M	-$1.45	N/A

Vyome presently has a consensus price target of $15.00, suggesting a potential upside of 577.51%. CollPlant Biotechnologies has a consensus price target of $11.50, suggesting a potential upside of 3,112.29%. Given CollPlant Biotechnologies' higher probable upside, analysts plainly believe CollPlant Biotechnologies is more favorable than Vyome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Vyome and Vyome both had 3 articles in the media. CollPlant Biotechnologies' average media sentiment score of 0.96 beat Vyome's score of 0.93 indicating that CollPlant Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vyome	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CollPlant Biotechnologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vyome beats CollPlant Biotechnologies on 10 of the 15 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to OSR?

OSR (NASDAQ:OSRH) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

In the previous week, CollPlant Biotechnologies had 1 more articles in the media than OSR. MarketBeat recorded 3 mentions for CollPlant Biotechnologies and 2 mentions for OSR. CollPlant Biotechnologies' average media sentiment score of 0.96 beat OSR's score of 0.62 indicating that CollPlant Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OSR	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CollPlant Biotechnologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OSR has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, CollPlant Biotechnologies has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

CollPlant Biotechnologies has a consensus price target of $11.50, indicating a potential upside of 3,112.29%. Given CollPlant Biotechnologies' stronger consensus rating and higher probable upside, analysts clearly believe CollPlant Biotechnologies is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

OSR has a net margin of -363.26% compared to CollPlant Biotechnologies' net margin of -683.68%. OSR's return on equity of -7.24% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OSR	-363.26%	-7.24%	-5.41%
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%

CollPlant Biotechnologies has lower revenue, but higher earnings than OSR. OSR is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$2.91M	3.97	-$27.06M	-$0.33	N/A
CollPlant Biotechnologies	$2.37M	2.18	-$11.49M	-$1.45	N/A

55.3% of OSR shares are held by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are held by institutional investors. 36.8% of OSR shares are held by company insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

OSR and CollPlant Biotechnologies tied by winning 8 of the 16 factors compared between the two stocks.

Get CollPlant Biotechnologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLGN vs. The Competition

Export

Metric	CollPlant Biotechnologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.16M	$3.66B	$6.81B	$12.57B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-0.25	21.44	27.52	25.33
Price / Sales	2.18	339.00	539.41	102.00
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	0.75	8.75	10.94	6.61
Net Income	-$11.49M	$23.87M	$3.57B	$336.72M
7 Day Performance	6.42%	3.51%	2.69%	2.63%
1 Month Performance	-10.72%	3.56%	1.84%	0.24%
1 Year Performance	-73.48%	67.21%	36.35%	29.97%

CollPlant Biotechnologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLGN CollPlant Biotechnologies	3.2157 of 5 stars	$0.36 +2.6%	$11.50 +3,112.3%	-74.6%	$5.16M	$2.37M	N/A	70	News Coverage Short Interest Decrease Gap Down
ZJYL Jin Medical International	0.5814 of 5 stars	$2.45 +0.8%	N/A	-86.0%	$19.02M	$20.69M	N/A	245	Analyst Downgrade Short Interest Increase
TMDIF Titan Medical	N/A	$0.16 -3.2%	N/A	-38.5%	$18.65M	$17.63M	N/A	50	Gap Up
ICCM IceCure Medical	3.718 of 5 stars	$6.12 +3.2%	$62.70 +924.5%	-83.7%	$16.64M	$3.38M	N/A	60	Gap Up
HIND Vyome	3.5193 of 5 stars	$2.12 -2.3%	$15.00 +607.5%	N/A	$15.23M	$320K	N/A	50	News Coverage High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLGN) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CollPlant Biotechnologies (CLGN) Competitors

CLGN vs. ZJYL, TMDIF, ICCM, HIND, and OSRH

How does CollPlant Biotechnologies compare to Jin Medical International?

Summary

How does CollPlant Biotechnologies compare to Titan Medical?

Summary

How does CollPlant Biotechnologies compare to IceCure Medical?

Summary

How does CollPlant Biotechnologies compare to Vyome?

Summary

How does CollPlant Biotechnologies compare to OSR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLGN vs. The Competition

CollPlant Biotechnologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CollPlant Biotechnologies (CLGN) Competitors

CLGN vs. ZJYL, TMDIF, ICCM, HIND, and OSRH

How does CollPlant Biotechnologies compare to Jin Medical International?

Do analysts recommend CLGN or ZJYL?

Does the media prefer CLGN or ZJYL?

Do insiders and institutionals hold more shares of CLGN or ZJYL?

Which has more risk & volatility, CLGN or ZJYL?

Which has preferable valuation and earnings, CLGN or ZJYL?

Is CLGN or ZJYL more profitable?

Summary

How does CollPlant Biotechnologies compare to Titan Medical?

Which has more risk and volatility, CLGN or TMDIF?

Which has stronger valuation and earnings, CLGN or TMDIF?

Does the media favor CLGN or TMDIF?

Do institutionals and insiders have more ownership in CLGN or TMDIF?

Is CLGN or TMDIF more profitable?

Do analysts recommend CLGN or TMDIF?

Summary

How does CollPlant Biotechnologies compare to IceCure Medical?

Does the media favor CLGN or ICCM?

Which has better earnings & valuation, CLGN or ICCM?

Do insiders and institutionals have more ownership in CLGN or ICCM?

Do analysts recommend CLGN or ICCM?

Is CLGN or ICCM more profitable?

Which has more volatility and risk, CLGN or ICCM?

Summary

How does CollPlant Biotechnologies compare to Vyome?

Which has more volatility & risk, HIND or CLGN?

Do institutionals and insiders hold more shares of HIND or CLGN?

Is HIND or CLGN more profitable?

Which has preferable earnings & valuation, HIND or CLGN?

Do analysts recommend HIND or CLGN?

Does the media favor HIND or CLGN?

Summary

How does CollPlant Biotechnologies compare to OSR?

Does the media refer more to OSRH or CLGN?

Which has more volatility and risk, OSRH or CLGN?

Do analysts recommend OSRH or CLGN?

Is OSRH or CLGN more profitable?

Which has stronger earnings and valuation, OSRH or CLGN?

Do institutionals and insiders have more ownership in OSRH or CLGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLGN vs. The Competition

CollPlant Biotechnologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools